Median Reduction of Seizure Frequency of 35.7% Over Placebo was Achieved in the 60 mg Treatment Arm Neurological Effects and Other Adverse Effects (AEs) Similar to Placebo NEW YORK, Jan. 30, 2023 ...
LEIDEN, The Netherlands, November 11, 2021 / B3C newswire / --SeraNovo BV (Leiden, The Netherlands) is pleased to announce the closing of a License Agreement with Équilibre BioPharmaceuticals ...
SeraNovo BV, an innovative formulation company, announced the closing of a License Agreement with Équilibre BioPharmaceuticals Corporation, a biopharmaceutical company engaged in the research and ...
Equilibre Biopharmaceuticals Corp. has positive top-line data from the phase II study of its lead asset, EQU-001, an anti-inflammatory adjunctive therapy for treating focal seizures for adults with ...
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback